Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | An overview of the biology of WHIM syndrome

David Dale • 10 Jun 2022
EHA 2022
Rare Diseases

David Dale, MD, University of Washington, Seattle, WA, summarizes the biology of WHIM syndrome, a disease that affects the CXCR4 gene and results in low white blood cell count and susceptibility to infections. Prof This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from David Dale

Diagnosis and treatment of neutropenia
0:46
Diagnosis and treatment of neutropenia
David Dale • 10 Jun 2022
4WHIM study: safety & efficacy of mavorixafor in patients with WHIM syndrome
0:34
4WHIM study: safety & efficacy of mavorixafor in patients with WHIM syndrome
David Dale • 10 Jun 2022

Related Videos

A new era for BCMA-targeted bispecific antibodies in AL amyloidosis?
1:49
A new era for BCMA-targeted bispecific antibodies in AL amyloidosis?
Giada Bianchi • 10 Sep 2026
Comparing treatment strategies for ATTR-CM across clinical outcomes: insights from a meta-analysis
2:21
Comparing treatment strategies for ATTR-CM across clinical outcomes: insights from a meta-analysis
Adolfo Calderón Fernández • 29 Aug 2026
Transitioning anselamimab into clinical practice: key challenges and opportunities
1:00
Transitioning anselamimab into clinical practice: key challenges and opportunities
Xiaowen Wang • 30 Aug 2026
Emerging therapeutic strategies and clinical trials in ATTR-CM
1:32
Emerging therapeutic strategies and clinical trials in ATTR-CM
Ronald Witteles • 29 Aug 2026
The content of VJHemOnc is intended for healthcare professionals